Clinical Trials Logo

Cholangitis clinical trials

View clinical trials related to Cholangitis.

Filter by:

NCT ID: NCT04678219 Recruiting - Clinical trials for Primary Sclerosing Cholangitis

A Pilot Study Examining Diet in Primary Sclerosing Cholangitis

DINER
Start date: August 28, 2020
Phase: N/A
Study type: Interventional

This research study is exploring the effects of dietary intervention in PSC. Study participants will be randomly assigned to either the Specific Carbohydrate Diet (SCD) or a vegan/low-sulfur diet for 8 weeks; the entire study will last approximately 14 weeks. Participants will work with BWH Registered Dieticians and receive dietary educational materials, recipes, and a food procurement stipend to support the new diet. Subjects will attend 7 video visits and have regular lab tests performed, requiring blood and stool samples.

NCT ID: NCT04663308 Recruiting - Clinical trials for Primary Sclerosing Cholangitis

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

VISTAS
Start date: December 18, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

NCT ID: NCT04650243 Recruiting - Clinical trials for Primary Biliary Cholangitis

Clinical Research of UCDA Reducing Medication Regimen in Stable PBC

UCDA PBC
Start date: March 21, 2020
Phase: Phase 4
Study type: Interventional

This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis. The participants will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at different level, while the control group will receive standard dosage of UDCA. The effect of therapy will be evaluated every three months.

NCT ID: NCT04620577 Recruiting - Clinical trials for The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice

The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice

Start date: October 20, 2020
Phase:
Study type: Observational

To investigate the influence of antibiotics on the incidence of biliary tract infections after PTCD for malignant obstructive jaundice.

NCT ID: NCT04618575 Recruiting - Hepatitis Clinical Trials

Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1

Start date: March 17, 2021
Phase: Phase 4
Study type: Interventional

A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with total glucosides of paeony in the treatment of PBC with AIH features 1

NCT ID: NCT04617561 Recruiting - Clinical trials for Primary Biliary Cholangitis

Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with low dose glucocorticoid in the treatment of PBC With AIH Features II to asses efficacy and safety.

NCT ID: NCT04514965 Recruiting - Clinical trials for Primary Biliary Cirrhosis

Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

Start date: October 1, 2020
Phase:
Study type: Observational

Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.

NCT ID: NCT04376528 Recruiting - Immunosuppression Clinical Trials

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Start date: June 16, 2021
Phase: Phase 4
Study type: Interventional

Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by mycophenolate mofetil versus cyclosporin A

NCT ID: NCT04309773 Recruiting - Clinical trials for Primary Sclerosing Cholangitis

Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

BEZASCLER
Start date: April 6, 2021
Phase: Phase 3
Study type: Interventional

The objectives of this study are to evaluate the effect of bezafibrate treatment compared to placebo on efficacy and safety in patients with primary sclerosing cholangitis (PSC) and persistent cholestasis despite ursodeoxycholic acid therapy

NCT ID: NCT04216745 Recruiting - Cholangitis Clinical Trials

Microbial Analysis in Patients With Cholangitis

Start date: March 1, 2020
Phase:
Study type: Observational

- To identify the microbial profile in bile and blood for patients with cholangitis. - To explore risk factors of cholangitis and outcomes in those patients